AIM Stock Summary and Trading Ideas (Aim Immunotech | AMEX:AIM)

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Aim Immunotech trades on the AMEX stock market under the symbol AIM.

As of March 27, 2023, AIM stock price declined to $0.40 with 88,505 million shares trading.

AIM has a beta of 0.81, meaning it tends to be less sensitive to market movements. AIM has a correlation of 0.06 to the broad based SPY ETF.

AIM has a market cap of $19.22 million. This is considered a Sub-Micro Cap stock.

Last quarter Aim Immunotech reported $21,000 in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-129,000 and missed earnings estimates by -$.05.

In the last 3 years, AIM stock traded as high as $4.30 and as low as $.29.

The top ETF exchange traded funds that AIM belongs to (by Net Assets): VTI, VXF, IWC, ITOT.

AIM has underperformed the market in the last year with a price return of -63.6% while the SPY ETF lost -10.4%. However, in the short term, AIM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.1% vs +4.1% return in SPY. But in the last 2 weeks, AIM shares have been beat by the market, returning -18.3% compared to an SPY return of +3.3%.

AIM support price is $.40 and resistance is $.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM stock will trade within this expected range on the day.